Search results

9 items
  1. The International Drug Control Regime and Access to Controlled Medicines

    • Christopher Hallam
    28 December 2014
    Policy briefing

    In poor and developing nations pain remains largely uncontrolled. Africa is the least well served continent for access to analgesia.

  2. Fatal Attraction: Brownfield's Flexibility Doctrine and Global Drug Policy Reform

    David Bewley-Taylor, Martin Jelsma, Damon Barrett
    19 November 2014
    Article

    State-level cannabis reforms have exposed the inability of the United States to abide by the terms of the legal bedrock of the global drug control system. It is calls for a conversation the US federal government wishes to avoid. The result is a new official position on the UN drugs treaties that, despite its seductively progressive tone, serves only to sustain the status quo and may cause damage beyond drug policy.

  3. Cross-regional statement on Drugs and Human Rights General Debate

    22 September 2014
    Article

    This is the first member states' crossregional statement on drugs and human rights in the human rights council.

  4. Preparing for the 2016 UNGASS on drugs

    Nazlee Maghsoudi
    30 July 2014
    Other news

    The United Nations General Assembly Special Session (UNGASS) on drugs in 2016 is intended to provide states with the opportunity to openly debate the future of international drug policies. An event at UN headquarters in New York discussed precisely what preparations are necessary to make sure the UNGASS accomplishes this objective.

  5. David Bewley-Taylor

    Profile
    Associate Fellow

    David Bewley Taylor is the founding Director of the Global Drug Policy Observatory at Swansea University, UK.  He has been researching various aspects of drug policy for over twenty years with his main areas of interest being US drug policy, the UN and international drug policy and more recently counter narcotics strategies in Afghanistan....

  6. Scheduling in the international drug control system

    • David Bewley-Taylor, Martin Jelsma, Christopher Hallam
    16 June 2014
    Policy briefing

    Scheduling is mostly prioritised in its repressive pole, though present debates are increasingly highlighting the need to modify the balance of the system in order to affirm the importance of the principle of health.

  7. UN High-Level Segment on Drugs, March 2014

    28 February 2014
    Article

    On March 13-14, 2014, UN member states will gather in Vienna, Austria, for a High Level Segment of the annual UN Commission on Narcotic Drugs (CND). The purpose of this meeting is to review the progress made, and the challenges encountered, since the 2009 Political Declaration and Plan of Action on the World Drug Problem. The main focus of the High Level Segment will be the negotiation of a Joint Ministerial Statement, which will set the scene for the 2016 UN General Assembly Special Session on Drugs (UNGASS), as well as recording member states’ views of progress.

  8. UNODC’s shifting position on drug policy: Progress and challenges

    • International Drug Policy Consortium (IDPC)
    31 January 2014
    Policy issue

    In March 2014, country delegations will gather at the United Nations Commission on Narcotic Drugs (CND) to review progress and challenges in international drug control since the agreement of a Political Declaration on drugs in 2009. Given that the Political Declaration aims to “eliminate or reduce significantly” the use, supply and demand of controlled drugs by 2019, this meeting represents an important opportunity for honest evaluation and an acknowledgement that these targets are not being achieved. With a United Nations General Assembly Special Session (UNGASS) on drugs just two years away, this is an important time for international drug control policy.

  9. UNODC Executive Director releases "contributions" ahead of CND High-Level Segment on drugs

    19 January 2014
    Article

    Ahead of the High-Level Segment on the world drug problem to take place on 13th and 14th January 2014, the UNODC Executive Director, Yuri Fedotov, has released his "contributions" to the debate. This 19-page document is, in parts, refreshingly honest about the “unequal” progress that has been made since 2009 (with reductions in supply or demand for some drugs in some places being offset by increases elsewhere), the setbacks and new challenges, and the fact that “the overall magnitude of drug demand has not substantially changed at the global level”.